Brineura
Biological
BioMarin Pharmaceutical Inc.
Total Payments
$5.3M
Transactions
1,684
Doctors
728
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $27,291 | 188 | 166 |
| 2023 | $743,621 | 255 | 151 |
| 2022 | $80,515 | 194 | 150 |
| 2021 | $111,936 | 185 | 154 |
| 2020 | $476,405 | 98 | 62 |
| 2019 | $1.3M | 260 | 67 |
| 2018 | $1.3M | 332 | 103 |
| 2017 | $1.1M | 172 | 96 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $4.6M | 170 | 87.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $377,345 | 98 | 7.2% |
| Education | $99,182 | 136 | 1.9% |
| Travel and Lodging | $94,521 | 149 | 1.8% |
| Food and Beverage | $53,897 | 1,121 | 1.0% |
| Consulting Fee | $13,185 | 8 | 0.3% |
| Grant | $3,000 | 2 | 0.1% |
Payments by Type
Research
$4.6M
170 transactions
General
$641,130
1,514 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Multicenter, Multinational, Extension Study to Evaluate the Long-Term Efficacy and Safety of BMN 190 in Patients With CLN2 Disease | BioMarin Pharmaceutical Inc. | $1.5M | 0 |
| A Phase 2, Open-Label, Multicenter Study to Evaluate Safety, Tolerability, and Efficacy of Intracerebroventricular BMN 190 in Pediatric Patients 18 Years of Age With CLN2 Disease | BioMarin Pharmaceutical Inc. | $1.1M | 1 |
| A Multicenter, Multi-national Open-label Program to Provide BMN 190 to Patients Diagnosed With CLN2 Disease | BioMarin Pharmaceutical Inc. | $591,034 | 0 |
| A Phase 2, Open-Label, Multicenter Study to Evaluate Safety, Tolerability, and Efficacy of Intracerebroventricular BMN 190 in Pediatric Patients < 18 Years of Age With CLN2 Disease | BioMarin Pharmaceutical Inc. | $579,146 | 0 |
| Intravitreal Enzyme Replacement Therapy to Prevent Retinal Disease Progression in Children with Neuronal Ceroid Lipofuscinosis Type 2 (CLN2) | BioMarin Pharmaceutical Inc. | $349,622 | 0 |
| Cerliponase alfa Observational Study (US) | BioMarin Pharmaceutical Inc. | $118,209 | 0 |
| Intravitreal Enzyme Replacement Therapy to Prevent Retinal Disease Progression in Children with Neuronal Ceroid Lipofuscinosis Type 2 (CLN2 | BioMarin Pharmaceutical Inc. | $113,382 | 0 |
| Examining Developmental Outcomes of Children Diagnosed wth CLN2 | BioMarin Pharmaceutical Inc. | $110,465 | 0 |
| Examining Developmental Outcomes of Children Diagnosed with CLN2 Disease | BioMarin Pharmaceutical Inc. | $50,000 | 0 |
| A Phase 2, Open-Label, Multicenter Study to Evaluate Safety, Tolerability, and Efficacy of Intracerebroventricular BMN 190 in Pediatric Patients 18 Years of Age With CLN2 Disease | BioMarin Pharmaceutical Inc. | $29,351 | 0 |
| Cerliponase alfa Observational Study US) | BioMarin Pharmaceutical Inc. | $20,210 | 0 |
| A Non-Interventional Observational Study of Pegvaliase-Naive Adults with Phenylketonuria PKU) Concept Elicitation and Cognitive Interviews | BioMarin Pharmaceutical Inc. | $14,178 | 0 |
| An Extension Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia | BioMarin Pharmaceutical Inc. | $8,768 | 0 |
| Cerliponase alfa Observational Study US | BioMarin Pharmaceutical Inc. | $5,400 | 0 |
| A Multicenter Multinational Extension Study to Evaluate the Long-Term Efficacy and Safety of BMN 190 in Patients With CLN2 Disease | BioMarin Pharmaceutical Inc. | $700.00 | 1 |
Top Doctors Receiving Payments for Brineura
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Orange, CA | $4.6M | 171 |
| , MD | Internal Medicine | New York, NY | $211,405 | 24 |
| , MD | Neurology with Special Qualifications in Child Neurology | Columbus, OH | $77,596 | 103 |
| , M.D | Neurodevelopmental Disabilities | Los Angeles, CA | $48,972 | 46 |
| , MD | Pediatrics | Orange, CA | $26,858 | 27 |
| , M.D | Neurology with Special Qualifications in Child Neurology | Chicago, IL | $19,552 | 29 |
| , MD | Neurology with Special Qualifications in Child Neurology | Pittsford, NY | $16,560 | 25 |
| , MD | Neurology | Rochester, MN | $10,866 | 25 |
| , MD | Neurology with Special Qualifications in Child Neurology | Columbus, OH | $10,815 | 14 |
| , MD | Neurology with Special Qualifications in Child Neurology | Charleston, SC | $9,973 | 6 |
| , M.D | Cardiovascular Disease | New York, NY | $9,000 | 1 |
| , MD | Clinical Neurophysiology | Miami, FL | $8,468 | 13 |
| , MD | Neurology | New York, NY | $7,695 | 11 |
| , M.D | Neurology with Special Qualifications in Child Neurology | Cincinnati, OH | $7,664 | 2 |
| Joffre Olaya | Student in an Organized Health Care Education/Training Program | North Tustin, CA | $7,621 | 11 |
| , M.D | Pediatrics | Oakland, CA | $7,510 | 10 |
| , MD | Clinical Genetics (M.D.) | Gainesville, FL | $7,500 | 1 |
| , MD | Neurology with Special Qualifications in Child Neurology | Aurora, CO | $7,004 | 21 |
| , MD | Retina Specialist | Boston, MA | $6,785 | 4 |
| , MD | Neurology with Special Qualifications in Child Neurology | Memphis, TN | $6,403 | 7 |
| , M.D | Clinical Genetics (M.D.) | New York, NY | $5,316 | 14 |
| , M.D., PH.D | Neurological Surgery | San Francisco, CA | $5,023 | 5 |
| , MD | Hematology & Oncology | Gainesville, FL | $5,023 | 5 |
| , MD | Orthopaedic Surgery | Seattle, WA | $4,711 | 14 |
| , M.D | Pediatrics | Chicago, IL | $4,397 | 7 |
Ad
Manufacturing Companies
Product Information
- Type Biological
- Total Payments $5.3M
- Total Doctors 728
- Transactions 1,684
About Brineura
Brineura is a biological associated with $5.3M in payments to 728 healthcare providers, recorded across 1,684 transactions in the CMS Open Payments database. The primary manufacturer is BioMarin Pharmaceutical Inc..
Payment data is available from 2017 to 2024. In 2024, $27,291 was paid across 188 transactions to 166 doctors.
The most common payment nature for Brineura is "Unspecified" ($4.6M, 87.8% of total).
Brineura is associated with 15 research studies, including "A Multicenter, Multinational, Extension Study to Evaluate the Long-Term Efficacy and Safety of BMN 190 in Patients With CLN2 Disease" ($1.5M).